Indonesia and Russia are advancing discussions on pharmaceutical technology transfers aimed at bolstering domestic medicine production and decreasing reliance on imports. This collaboration comes as both nations seek to improve regulatory oversight of medicines and food products.
Key talks were held between Indonesia’s Food and Drug Authority (BPOM), headed by Taruna Ikrar, and Russian Deputy Minister of Industry and Trade Alexey Vladimirovich Gruzdev. The discussions focused on pharmaceutical manufacturing, quality inspections, and the use of digital technologies to enhance product safety and traceability.
Indonesia emphasized the need to expand local production of essential healthcare products, particularly diabetes treatments such as insulin and glucagon-like peptide-1 (GLP-1) medicines. Other potential areas of cooperation include cancer treatments, monoclonal antibodies, antiviral medicines, and advanced biotechnology products.
Russian companies have shown interest in transferring technology and potentially setting up manufacturing facilities in Indonesia, particularly for insulin, oncology medicines, and biotechnology products. The Russian delegation noted that several Russian pharmaceutical firms have already submitted product registration documents to BPOM.
The two countries are reviewing existing cooperation efforts, which include Good Manufacturing Practice (GMP) inspections, technical training, and information sharing. They are also working on finalizing a memorandum of understanding to establish a framework for deeper collaboration.
As part of the discussions, Russia proposed exploring mutual recognition of GMP certificates to simplify regulatory procedures and facilitate market access for pharmaceuticals in both countries. This proposal will require further dialogue to ensure compatibility between their regulatory systems.
To enhance Indonesia’s inspection capabilities, Russia offered technical training, including virtual reality-based simulations to prepare inspectors for pharmaceutical manufacturing assessments. The discussions also covered digital regulatory systems and supply-chain monitoring, with both sides expressing interest in continuing negotiations and expanding cooperation through future meetings and visits to pharmaceutical manufacturing facilities.